Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons.

Abstract

Leucine-rich repeat kinase-2 (LRRK2) mutations are the most important cause of familial Parkinson's disease, and non-selective inhibitors are protective in rodent disease models. Because of their poor potency and selectivity, the neuroprotective mechanism of these tool compounds has remained elusive so far, and it is still unknown whether selective LRRK2 inhibition can attenuate mutant LRRK2-dependent toxicity in human neurons. Here, we employ a chemoproteomics strategy to identify potent, selective, and metabolically stable LRRK2 inhibitors. We demonstrate that CZC-25146 prevents mutant LRRK2-induced injury of cultured rodent and human neurons with mid-nanomolar potency. These precise chemical probes further validate this emerging therapeutic strategy. They will enable more detailed studies of LRRK2-dependent signaling and pathogenesis and accelerate drug discovery.

• Authors: Nigel Ramsden, Jessica Perrin, Zhao Ren, Byoung Dae Lee, Nico Zinn, Valina L Dawson, Danny Tam, Michael Bova, Manja Lang, Gerard Drewes, Marcus Bantscheff, Frederique Bard, Ted M Dawson, Carsten Hopf
• Journal: ACS chemical biology (ACS Chem Biol) Vol. 6 Issue 10 Pg. 1021-8 (Oct 21 2011) ISSN: 1554-8937 [Electronic] United States
• PMID: 21812418 (Publication Type: Letter)

Chemical References

• Protein Kinase Inhibitors
• LRRK2 protein, human
• Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
• Protein Serine-Threonine Kinases

Topics

• Animals
• Cells, Cultured
• Drug Design
• Humans
• Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
• Mutation
• Neurons (drug effects, metabolism, pathology)
• Parkinson Disease (drug therapy, genetics, pathology)
• Protein Kinase Inhibitors (chemistry, pharmacology)
• Protein Serine-Threonine Kinases (antagonists & inhibitors, genetics)
• Proteomics (methods)
• Rats